Lantern Pharma Inc.
LTRN
$3.16
-$0.03-0.94%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.18% | 11.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.04% | 13.84% | |||
| Operating Income | 19.04% | -13.84% | |||
| Income Before Tax | 22.78% | -30.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22.78% | -30.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.78% | -30.39% | |||
| EBIT | 19.04% | -13.84% | |||
| EBITDA | 19.05% | -13.85% | |||
| EPS Basic | 22.09% | -29.00% | |||
| Normalized Basic EPS | 16.35% | -24.16% | |||
| EPS Diluted | 22.09% | -29.00% | |||
| Normalized Diluted EPS | 16.35% | -24.16% | |||
| Average Basic Shares Outstanding | -0.88% | 1.08% | |||
| Average Diluted Shares Outstanding | -0.88% | 1.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||